By Elana Gotkine HealthDay Reporter>TUESDAY, Sept. 19, 2023 -- For children with sickle cell disease (SCD), the rates of invasive pneumococcal infection (IPD) have decreased since introduction of pneumococcal conjugate vaccines (PCVs), according to a study published online Sept. 12 in Blood Advances.Thomas V.

由Elana Gotkine HealthDay记者>2023年9月19日星期二-对于镰状细胞病（SCD）患儿，根据一项研究，自引入肺炎球菌结合疫苗（PCV）以来，侵入性肺炎球菌感染（IPD）的发病率有所下降9月12日在线发表在Blood Advances.Thomas V。

Adamkiewicz, M.D., from the Morehouse School of Medicine in Atlanta, and colleagues examined trends in IPD in children with SCD using data from the Georgia Emerging Infections Program/Centers for Disease Control and Prevention Active Bacterial Core Surveillance network.The researchers identified 104 IPD episodes over 25 years among 3,707 children with hemoglobin SS (HbSS) or hemoglobin SC who were younger than 10 years.

亚特兰大Morehouse医学院的Adamkiewicz博士及其同事使用佐治亚州新发感染计划/疾病控制和预防中心活动细菌核心监测网络的数据，检查了SCD儿童IPD的趋势。研究人员在3707名年龄小于10岁的血红蛋白SS（HbSS）或血红蛋白SC患儿中发现了超过25年的104次IPD发作。

Among children with HbSS aged 0 to 4 and 5 to 9 years, there was a decrease in IPD of 87 and 80 percent, respectively, from 1994-1999 to 2010-2018. However, during this period, there was an increase in the IPD incidence rate ratios when comparing children with SCD with the reference population, from 20.2 to 29.2.

在0至4岁和5至9岁的HbSS儿童中，从1994-1999年到2010-2018年，IPD分别下降了87%和80%。然而，在此期间，将SCD儿童与参考人群进行比较时，IPD发病率比率从20.2增加到29.2。

After 2010, all IPD serotypes identified were those not included in the 13-valent PCV (PCV13). The effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) against non-PCV13 serotypes included in PPSV23 plus 15A/15C was 92 percent within three years of vaccination. PPSV23 would cover 62 percent of non-PCV13-serotype IPD in children with SCD, while 16, 51, and 92 percent would be covered by PCV15, PCV20, and PCV21/V116 (in development), respectively.'IPD remains a persistent, life-threatening risk in children with SCD, thus underscoring the need for vaccines with broader serotype coverage and continued IPD surveillance to identify emerging targets for vaccines and other prophylactic strategies,' the authors write.One autho.

2010年以后，所有确定的IPD血清型都不包括在13价PCV（PCV13）中。23价肺炎球菌多糖疫苗（PPSV23）对PPSV23加15A/15C中包含的非PCV13血清型的有效性在接种疫苗后三年内为92%。PPSV23将覆盖SCD儿童中62%的非PCV13血清型IPD，而PCV15，PCV20和PCV21/V116（正在开发中）将分别覆盖16%，51%和92%作者写道，IPD仍然是SCD儿童持续存在的威胁生命的风险，因此强调需要具有更广泛血清型覆盖率的疫苗，并继续进行IPD监测以确定疫苗和其他预防策略的新目标。一位作者。